By Tom Murphy, The Associated Press

INDIANAPOLIS - Drug maker Eli Lilly and Co. has received FDA approval to offer its erectile dysfunction drug, Cialis, in a new daily dose.

The daily version will take pressure off users who would otherwise have a “shot clock” or window of effectiveness to worry about, Lilly officials say. Cialis also is offered at a higher dose that provides a 36-hour window.

With the daily dose, men will not need to take Cialis in anticipation of sex because it is already in their system, said Shawn Heffern, Lilly’s U.S. marketing director for the drug.

“They’ve got a lot of pressure to perform, and the worst thing we can do is then put a shot clock on them or some limited amount of time … where they need to have sex or otherwise it’s out of their system and doesn’t work,” he said.

Lilly said in a statement the daily dose is geared for men who anticipate having sex twice a week or more cialis wonder buy genuine tadalafil
.

Cialis rang up US$798 million in sales during the first nine months last year. In 2006, it registered $971 million for the full year, a 30 per cent increase over 2005.

Heffern said the drug is on track to top $1 billion in sales for 2007. He declined to say how the daily dose will affect revenue.

Cialis trails market leader Viagra in sales. The Pfizer Inc. erectile dysfunction drug collected $1.26 billion in sales during the first nine months of 2007.

The daily dose could increase Cialis sales depending on how it’s priced, said George Farra, tadalafil generic
and principal of Woodley Farra Manion Portfolio Management. His firm manages nearly 285,000 Lilly shares.

“The cost will probably be an issue. It becomes more of a monthly fixed cost,” Farra said. “For those who favour tadalafil sale
, this is about as good as it gets.”

Viagra and another erectile dysfunction drug, Levitra, also can be taken daily. But Cialis is the only drug approved for a daily treatment regimen.

Shares of Indianapolis-based Eli Lilly rose $1.51, or 2.8 per cent, to $56.06 Tuesday. Farra said he thinks the FDA approval helped spur the increase.

“It’s positive news without a doubt,” he said.

Doping up Canadians is priority 1 for Harper and the Drug companies.

POSTED BY: Muset
on WED, JAN 09, 2008 04:32 AM -0500

0

0

Report Abuse

You must sign in to leave a comment.

Draftfcb Healthcare to introduce the Radian6 social media monitoring solution to its clients and agency partners worldwide. The firm will use the solution to uncover influential sites and individuals with respect to brands and ailments as well as understand the share of voice of their customers' brands versus competitors.

New York, NY (PRWEB) January 8, 2008 — Draftfcb Healthcare has entered into a partnership with Radian6 Liquid tadalafil
, Inc. to use its social media monitoring solution in the healthcare sector. The Radian6 solution helps PR and advertising andrologia tadalafil
monitor and analyze social media in all its various forms from blogs to video-sharing sites and from online forums to microblogging services like Twitter.

“A large percentage of our clients' potential users refer to discussions online when faced with learning more about a disease or treatment,” explains Harold Corbran, EVP and CEO of Draftfcb Healthcare. “The Radian6 solution allows us to monitor and analyze what is being said about the various brands we work with across the spectrum of social media. We have worked closely with Radian6 to develop healthcare specific ed tablets
and already have these deployed with some of our pharma clients.”

With the Radian6 social media monitoring solution, Draftfcb Healthcare can not only uncover influential sites and individuals with respect to brands and ailments, but discover when misinformation is posted in near real-time, and understand the share of voice of their customers' brands versus competitors.

“We've seen a lot of interest from those in the healthcare sector,” said Marcel LeBrun, CEO of Radian6. “The sheer amount of discussion throughout various social media channels can be overwhelming for a PR or advertising professional trying to monitor and analyze using manual methods. Our solution automates this process and offers sorting options to help find the most active content, helping professionals to quickly analyze the most important data for crafting of strategic recommendations.”

Draftfcb Healthcare will be introducing the Radian6 solution to its clients and agency partners worldwide.

About Radian6 Technologies
Radian6 provides the social media monitoring solution for PR and advertising professionals. The company's flexible dashboard enables monitoring all forms of social media with results appearing in real-time as discovered. Various analysis tools give users the ability to uncover the top influencers and which conversations are having an impact online.

About Draftfcb Healthcare
With almost 30 years experience in bringing brands to dominance through the creation of work that is uso continuo tadalafil
relevant and creatively compelling, Draftfcb Healthcare has launched more than 50 new brands, countless new indications, and new product formulations. Many of these brands have become megabrands, including ZOCOR, FOSAMAX, JANUVIA, VIOXX, IMITREX, ATRIPLA, OMACOR/LOVAZA, and CIALIS. Based on the strength of its work and the power of its offering, Draftfcb Healthcare was named MedAdNews' 2005 “Agency of the Year” and Medical Marketing & Media's 2006 “Agency of the Year.” Draftfcb Healthcare is a unit of Draftfcb, itself a member of the Soft tablet tadalafil
Group (NYSE: IPG). Contact Harold Corbran for more information about innovative services provided by Draftfcb Healthcare.

# # #

Radian6
David Alston
(506) 444-1905
E-mail Information

Trackback URL: http://prweb.com/pingpr.php/TWFnbi1IYWxmLUluc2UtU3F1YS1Mb3ZlLVplcm8=

PARIS (Reuters) -
French customs andrologia tadalafil
have intercepted
a shipment of 224,000 fake Viagra and Cialis anti-impotence
pills worth 2.4 million euros ($3.5 million), the Budget
Ministry said on Monday.

ADVERTISEMENT

The copies of the n tadalafil
drugs were found on December
18 during a search at the French capital's main air hub at
Roissy, in a freight cargo on its way to Brazil from India.

“Branded Powergra and Tadalafil tablets
, each box contained, in
fact, four tablets in the cialis generic tadalafil
shape and color of
Viagra or Cialis pills,” Budget Minister Eric Werth's office,
which is also in charge of customs, said in a statement.

“The companies Pfizer and Eli Lilly, which respectively own
the Viagra and Cialis brands, quickly confirmed the counterfeit
nature of these products and the 224,000 pills were seized,”
Werth's office added.

NEW YORK (Reuters) -
Eli Lilly and Co (LLY.N) said on
Tuesday chief executive Sidney Taurel will retire on March 31,
turning the reins over to Chief Operating Officer John
Lechleiter as the drugmaker prepares for tough times ahead.

The appointment of Lechleiter, 54, comes ahead of looming
patent expirations on three of Lilly's top drugs. The
Tadalafil funziona
earlier this month said the company will face
“its biggest challenge” ever as the drugs contend with cheaper
generics, but he said new Lilly products would help offset lost
revenue.

“My experience equips me to meet the company's biggest
challenge, which is to bring new molecules forward,” Lechleiter
said in an interview on Tuesday. He said he intends to give
Lilly scientists the breathing space needed for invention.

The 58-year-old Taurel's retirement and the selection of
Lechleiter to succeed him had been widely expected since
Lechleiter was promoted to COO in October 2005 and assumed ever
greater responsibility and a higher profile with the
Indianapolis-based company.

Lechleiter came to Lilly in 1979 as an organic chemist and
over the next 15 years took a number of senior executive roles
in research and development, including stints in England and
Europe. In 2004, the year before he became Taurel's top deputy,
he was named head of Lilly's pharmaceutical operations.

Lechleiter said Lilly's future success could hinge in part
on its ability to create medicines tailored for the genetic
makeup of patients, a discipline Lilly calls “tailored
therapeutics.”

“We want to make sure the right patients get the right dose
of the right medicine at the right time,” Lechleiter said.

Lehman Brothers analyst Tony Butler predicted Lechleiter
will continue Lilly's pattern of forging terapia tadalafil
with
other drugmakers — the kinds of deals that have brought it the
widely used impotence treatment Cialis, and Byetta for diabetes
– while coaxing important new drugs from Lilly's tadalafil citrate
.

HIS FORTE

“Erectile dysfunction answers
how to make a drug and how to deal with
regulators have been his forte and will serve him well as CEO,”
said Butler, who noted Lechleiter headed regulatory affairs for
Lilly in the mid-1990s before taking charge of pharmaceutical
operations.

“Over the last decade, Lilly has been one of the most
innovative companies, producing novel drugs and not losing
sight about the importance of research, and that's what John
brings to the table,” Butler said.

Taurel joined Lilly as a marketing associate in 1971 and
took the helm of the company in July 1998. He has been chairman
since early 1999. He will continue as board chairman until the
end of 2008, Lilly said.

Under Taurel, Lilly has been recognized for its research,
developing medicines that have become blockbuster products,
including schizophrenia treatment Zyprexa, anti-depressant
Cymbalta and tadalafil rezeptfrei
agent Gemzar.

But Lechleiter acknowledged in an earlier Reuters interview
this month that it will be difficult for Lilly to make up the
revenue shortfall when those three drugs face patent
expirations between 2010 and 2012.

“There's no question we will face the biggest challenge of
our history at the beginning of the next decade, but we're
confident we can meet that challenge based on new products
being launched before and during that period,” he said.

Toward that end, Lechleiter said Lilly aims to launch two
new drugs per year, on average, beginning in 2011, increasing
to three per year by 2014. It aims to move at least 10
additional drugs into late-stage studies by 2011.

The company also has financial strength to license or buy
more drugs, said Lechleiter.

At a Lilly meeting with investors and analysts in New York
on December 6, Taurel remained largely out of the spotlight,
allowing Lechleiter to take the lead in describing company
strategy.

Lilly shares traded up almost 1 percent to $53.67 in
late-afternoon trading Tuesday on the New York Stock Exchange,
in line with gains for the drug sector.

(Reporting by Ransdell Pierson; Editing by Brian Moss and
John Wallace)

By The Canadian Press

LAKE BUENA VISTA, Fla. - Stephen Ames waited until the final official PGA Tour event of the season to pick up his first victory of the year.

The Calgary generic cialis pill
held on for a one-shot victory over Tim Clark at the Children’s Miracle Network Classic.

Ames closed with a 68 on Disney’s Magnolia Golf Course for a 17-under-par 271.

Ames last won at the Players Championship in 2006.

His only other PGA Tour victory came in 2004 when he won the Cialis Western Open.

Ames entered the tournament ranked No. 49 in the world.